In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
Delayed reward discounting predicts treatment response for heavy drinkers receiving smoking cessation treatment.
Delayed reward discounting ( DRD ) is a behavioral economic index of impulsivity that reflects the extent to which an individual devalues a reward based on its delay in time ( i.e. , preference for smaller immediate rewards relative to larger delayed rewards ) . Current smokers exhibit greater DRD compared to non-smokers , but also exhibit greater DRD compared to ex-smokers , suggesting that either DRD is inversely associated with successful smoking cessation or that smoking cessation itself reduces DRD . In a sample of treatment-seeking smokers ( n=57 , 61 % male , 85 % Caucasian ) participating in a r and omized controlled smoking cessation trial , the current study prospect ively examined  DRD  for money in general and at three magnitudes in relation to time to the participants ' first lapse to smoking . Survival analysis using Cox proportional-hazards regression revealed that DRD predicted days to first lapse ( ps<.05-.01 ) and did so beyond nicotine dependence , sensation-seeking , and income in covariate analyses , with the exception of small magnitude discounting . In addition , dichotomous comparisons revealed significantly more impulsive baseline discounting for individuals who had lapsed by the two-week and eight-week follow-up visits . These findings indicate that high levels of DRD reflect a risk factor for poor smoking cessation treatment response . Interrelationships among the variables assessed and clinical strategies to improve outcomes for smokers who are high in DRD are discussed
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .